
PALE-DSR Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
PALE-DSR
Pantoprazole 40mg + Domperidone 30mg (sustained release)
PALE-DSR is an advanced gastro-protective formulation developed for the rapid healing of mucosal erosion, acid peptic disorders, and gastroesophageal reflux disease (GERD).
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
Forms a polyanionic protective barrier coating over inflamed gastric ulcers, preventing enzymatic acid degradation while facilitating tissue re-epithelialization.
Administer on an empty stomach 1 hour before principal meals, or as posology prescribed by the gastroenterologist.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store below 25°C in a dry place. Protect from moisture and direct sunlight.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
PALE-DSR features Pantoprazole 40mg + Domperidone 30mg (sustained release) prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Customer & Clinical Reviews
Real feedback from registered physicians, stockists, PCD franchise partners, and verified buyers.
Based on 1 verified review
Evaluated across our institutional for PALE-DSR
PALE-DSR has been evaluated across our institutional healthcare network, leading to verified clinical improvement without secondary complaints or nausea. The pack design is aesthetically modern with distinct therapeutic labeling that eliminates dispensing errors. Both consulting doctors and stocking pharmacists rate this formulation among the best in its class.
Questions Regarding PALE-DSR
What is the therapeutic indication and composition of PALE-DSR?
PALE-DSR contains Pantoprazole 40mg + Domperidone 30mg (sustained release) indicated for Peptic Ulcer Disease as formulated by Sygnus Biotech.
What packaging presentations are available for PALE-DSR?
PALE-DSR is supplied in tamper-evident 10 x 10 Blister Pack / 30 Softgels Bottle, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for PALE-DSR?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for PALE-DSR along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
PALE-DSR is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.





